The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
HER2-negative Breast Cancer Treatment-Global Market Insights and Sales Trends 2024
Synopsis
HER2 (human epidermal growth factor receptor 2) is a protein that appears on the surface of some breast cancer cells. It may also be called HER2/neu or ErbB2.HER2-negative breast cancer means that the people have little or no HER2 protein.
The global HER2-negative Breast Cancer Treatment market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of HER2-negative Breast Cancer Treatment in various end use industries. The expanding demands from the Hosptial and Clinic, are propelling HER2-negative Breast Cancer Treatment market. Chemotherapy, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Surgery segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for HER2-negative Breast Cancer Treatment, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global HER2-negative Breast Cancer Treatment market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global HER2-negative Breast Cancer Treatment market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, HER2-negative Breast Cancer Treatment sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of HER2-negative Breast Cancer Treatment covered in this report include AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Pfizer, Novartis, Pfizer, GlaxoSmithKline, Novartis and Merck, etc.
The global HER2-negative Breast Cancer Treatment market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
AstraZeneca
Bristol-Myers Squibb
Eli Lilly
Pfizer
Novartis
Pfizer
GlaxoSmithKline
Novartis
Merck
Eli Lilly
Global HER2-negative Breast Cancer Treatment market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global HER2-negative Breast Cancer Treatment market, Segment by Type:
Chemotherapy
Surgery
Radiation
Hormonal therapy/endocrine therapy
Global HER2-negative Breast Cancer Treatment market, by Application
Hosptial
Clinic
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of HER2-negative Breast Cancer Treatment companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
HER2 (human epidermal growth factor receptor 2) is a protein that appears on the surface of some breast cancer cells. It may also be called HER2/neu or ErbB2.HER2-negative breast cancer means that the people have little or no HER2 protein.
The global HER2-negative Breast Cancer Treatment market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of HER2-negative Breast Cancer Treatment in various end use industries. The expanding demands from the Hosptial and Clinic, are propelling HER2-negative Breast Cancer Treatment market. Chemotherapy, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Surgery segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for HER2-negative Breast Cancer Treatment, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global HER2-negative Breast Cancer Treatment market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global HER2-negative Breast Cancer Treatment market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, HER2-negative Breast Cancer Treatment sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of HER2-negative Breast Cancer Treatment covered in this report include AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Pfizer, Novartis, Pfizer, GlaxoSmithKline, Novartis and Merck, etc.
The global HER2-negative Breast Cancer Treatment market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
AstraZeneca
Bristol-Myers Squibb
Eli Lilly
Pfizer
Novartis
Pfizer
GlaxoSmithKline
Novartis
Merck
Eli Lilly
Global HER2-negative Breast Cancer Treatment market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global HER2-negative Breast Cancer Treatment market, Segment by Type:
Chemotherapy
Surgery
Radiation
Hormonal therapy/endocrine therapy
Global HER2-negative Breast Cancer Treatment market, by Application
Hosptial
Clinic
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of HER2-negative Breast Cancer Treatment companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of HER2-negative Breast Cancer Treatment
1.1 HER2-negative Breast Cancer Treatment Market Overview
1.1.1 HER2-negative Breast Cancer Treatment Product Scope
1.1.2 HER2-negative Breast Cancer Treatment Market Status and Outlook
1.2 Global HER2-negative Breast Cancer Treatment Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global HER2-negative Breast Cancer Treatment Market Size by Region (2018-2029)
1.4 Global HER2-negative Breast Cancer Treatment Historic Market Size by Region (2018-2023)
1.5 Global HER2-negative Breast Cancer Treatment Market Size Forecast by Region (2024-2029)
1.6 Key Regions, HER2-negative Breast Cancer Treatment Market Size (2018-2029)
1.6.1 North America HER2-negative Breast Cancer Treatment Market Size (2018-2029)
1.6.2 Europe HER2-negative Breast Cancer Treatment Market Size (2018-2029)
1.6.3 Asia-Pacific HER2-negative Breast Cancer Treatment Market Size (2018-2029)
1.6.4 Latin America HER2-negative Breast Cancer Treatment Market Size (2018-2029)
1.6.5 Middle East & Africa HER2-negative Breast Cancer Treatment Market Size (2018-2029)
2 HER2-negative Breast Cancer Treatment Market by Type
2.1 Introduction
2.1.1 Chemotherapy
2.1.2 Surgery
2.1.3 Radiation
2.1.4 Hormonal therapy/endocrine therapy
2.2 Global HER2-negative Breast Cancer Treatment Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global HER2-negative Breast Cancer Treatment Historic Market Size by Type (2018-2023)
2.2.2 Global HER2-negative Breast Cancer Treatment Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America HER2-negative Breast Cancer Treatment Revenue Breakdown by Type (2018-2029)
2.3.2 Europe HER2-negative Breast Cancer Treatment Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific HER2-negative Breast Cancer Treatment Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America HER2-negative Breast Cancer Treatment Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa HER2-negative Breast Cancer Treatment Revenue Breakdown by Type (2018-2029)
3 HER2-negative Breast Cancer Treatment Market Overview by Application
3.1 Introduction
3.1.1 Hosptial
3.1.2 Clinic
3.2 Global HER2-negative Breast Cancer Treatment Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global HER2-negative Breast Cancer Treatment Historic Market Size by Application (2018-2023)
3.2.2 Global HER2-negative Breast Cancer Treatment Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America HER2-negative Breast Cancer Treatment Revenue Breakdown by Application (2018-2029)
3.3.2 Europe HER2-negative Breast Cancer Treatment Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific HER2-negative Breast Cancer Treatment Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America HER2-negative Breast Cancer Treatment Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa HER2-negative Breast Cancer Treatment Revenue Breakdown by Application (2018-2029)
4 HER2-negative Breast Cancer Treatment Competition Analysis by Players
4.1 Global HER2-negative Breast Cancer Treatment Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in HER2-negative Breast Cancer Treatment as of 2022)
4.3 Date of Key Players Enter into HER2-negative Breast Cancer Treatment Market
4.4 Global Top Players HER2-negative Breast Cancer Treatment Headquarters and Area Served
4.5 Key Players HER2-negative Breast Cancer Treatment Product Solution and Service
4.6 Competitive Status
4.6.1 HER2-negative Breast Cancer Treatment Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 AstraZeneca
5.1.1 AstraZeneca Profile
5.1.2 AstraZeneca Main Business
5.1.3 AstraZeneca HER2-negative Breast Cancer Treatment Products, Services and Solutions
5.1.4 AstraZeneca HER2-negative Breast Cancer Treatment Revenue (US$ Million) & (2018-2023)
5.1.5 AstraZeneca Recent Developments
5.2 Bristol-Myers Squibb
5.2.1 Bristol-Myers Squibb Profile
5.2.2 Bristol-Myers Squibb Main Business
5.2.3 Bristol-Myers Squibb HER2-negative Breast Cancer Treatment Products, Services and Solutions
5.2.4 Bristol-Myers Squibb HER2-negative Breast Cancer Treatment Revenue (US$ Million) & (2018-2023)
5.2.5 Bristol-Myers Squibb Recent Developments
5.3 Eli Lilly
5.3.1 Eli Lilly Profile
5.3.2 Eli Lilly Main Business
5.3.3 Eli Lilly HER2-negative Breast Cancer Treatment Products, Services and Solutions
5.3.4 Eli Lilly HER2-negative Breast Cancer Treatment Revenue (US$ Million) & (2018-2023)
5.3.5 Pfizer Recent Developments
5.4 Pfizer
5.4.1 Pfizer Profile
5.4.2 Pfizer Main Business
5.4.3 Pfizer HER2-negative Breast Cancer Treatment Products, Services and Solutions
5.4.4 Pfizer HER2-negative Breast Cancer Treatment Revenue (US$ Million) & (2018-2023)
5.4.5 Pfizer Recent Developments
5.5 Novartis
5.5.1 Novartis Profile
5.5.2 Novartis Main Business
5.5.3 Novartis HER2-negative Breast Cancer Treatment Products, Services and Solutions
5.5.4 Novartis HER2-negative Breast Cancer Treatment Revenue (US$ Million) & (2018-2023)
5.5.5 Novartis Recent Developments
5.6 Pfizer
5.6.1 Pfizer Profile
5.6.2 Pfizer Main Business
5.6.3 Pfizer HER2-negative Breast Cancer Treatment Products, Services and Solutions
5.6.4 Pfizer HER2-negative Breast Cancer Treatment Revenue (US$ Million) & (2018-2023)
5.6.5 Pfizer Recent Developments
5.7 GlaxoSmithKline
5.7.1 GlaxoSmithKline Profile
5.7.2 GlaxoSmithKline Main Business
5.7.3 GlaxoSmithKline HER2-negative Breast Cancer Treatment Products, Services and Solutions
5.7.4 GlaxoSmithKline HER2-negative Breast Cancer Treatment Revenue (US$ Million) & (2018-2023)
5.7.5 GlaxoSmithKline Recent Developments
5.8 Novartis
5.8.1 Novartis Profile
5.8.2 Novartis Main Business
5.8.3 Novartis HER2-negative Breast Cancer Treatment Products, Services and Solutions
5.8.4 Novartis HER2-negative Breast Cancer Treatment Revenue (US$ Million) & (2018-2023)
5.8.5 Novartis Recent Developments
5.9 Merck
5.9.1 Merck Profile
5.9.2 Merck Main Business
5.9.3 Merck HER2-negative Breast Cancer Treatment Products, Services and Solutions
5.9.4 Merck HER2-negative Breast Cancer Treatment Revenue (US$ Million) & (2018-2023)
5.9.5 Merck Recent Developments
5.10 Eli Lilly
5.10.1 Eli Lilly Profile
5.10.2 Eli Lilly Main Business
5.10.3 Eli Lilly HER2-negative Breast Cancer Treatment Products, Services and Solutions
5.10.4 Eli Lilly HER2-negative Breast Cancer Treatment Revenue (US$ Million) & (2018-2023)
5.10.5 Eli Lilly Recent Developments
6 North America
6.1 North America HER2-negative Breast Cancer Treatment Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe HER2-negative Breast Cancer Treatment Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific HER2-negative Breast Cancer Treatment Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America HER2-negative Breast Cancer Treatment Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa HER2-negative Breast Cancer Treatment Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 HER2-negative Breast Cancer Treatment Market Dynamics
11.1 HER2-negative Breast Cancer Treatment Industry Trends
11.2 HER2-negative Breast Cancer Treatment Market Drivers
11.3 HER2-negative Breast Cancer Treatment Market Challenges
11.4 HER2-negative Breast Cancer Treatment Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
